155 related articles for article (PubMed ID: 30554838)
21. Comparative effectiveness research using claims data: meticulous methods don't solve old problems.
Ruzieh M
Eur Heart J; 2024 Apr; 45(14):1284. PubMed ID: 38252975
[No Abstract] [Full Text] [Related]
22. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on fluid distribution: A comparison study with furosemide and tolvaptan.
Ohara K; Masuda T; Murakami T; Imai T; Yoshizawa H; Nakagawa S; Okada M; Miki A; Myoga A; Sugase T; Sekiguchi C; Miyazawa Y; Maeshima A; Akimoto T; Saito O; Muto S; Nagata D
Nephrology (Carlton); 2019 Sep; 24(9):904-911. PubMed ID: 30578654
[TBL] [Abstract][Full Text] [Related]
23. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
[TBL] [Abstract][Full Text] [Related]
24. Clinical potential of canagliflozin in cardiovascular risk reduction in patients with type 2 diabetes.
Skelley JW; Carter BS; Roberts MZ
Vasc Health Risk Manag; 2018; 14():419-428. PubMed ID: 30573964
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis.
Seko Y; Nishikawa T; Umemura A; Yamaguchi K; Moriguchi M; Yasui K; Kimura M; Iijima H; Hashimoto T; Sumida Y; Okanoue T; Itoh Y
Diabetes Metab Syndr Obes; 2018; 11():835-843. PubMed ID: 30568471
[TBL] [Abstract][Full Text] [Related]
26. Could renin-angiotensin-aldosterone system activation explain the amputations associated with canagliflozin? The nitric oxide hypothesis.
León Jiménez D; López Chozas JM; Espino Montoro A; Rico Corral MÁ; Castilla Guerra L; Miramontes González JP
Diabetes Res Clin Pract; 2019 Feb; 148():10-13. PubMed ID: 30583037
[No Abstract] [Full Text] [Related]
27. Sustained fasting glucose oxidation and postprandial lipid oxidation associated with reduced insulin dose in type 2 diabetes with sodium-glucose cotransporter 2 inhibitor: A randomized, open-label, prospective study.
Kanazawa K; Uchino H; Shigiyama F; Igarashi H; Ikehara K; Yoshikawa F; Usui S; Miyagi M; Yoshino H; Ando Y; Kumashiro N; Hirose T
J Diabetes Investig; 2019 Jul; 10(4):1022-1031. PubMed ID: 30582774
[TBL] [Abstract][Full Text] [Related]
28. Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus.
Akuta N; Kawamura Y; Watanabe C; Nishimura A; Okubo M; Mori Y; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Suzuki F; Suzuki Y; Arase Y; Ikeda K; Kumada H
Hepatol Res; 2019 May; 49(5):531-539. PubMed ID: 30577089
[TBL] [Abstract][Full Text] [Related]
29. Canagliflozin and Stroke in Type 2 Diabetes Mellitus.
Zhou Z; Lindley RI; Rådholm K; Jenkins B; Watson J; Perkovic V; Mahaffey KW; de Zeeuw D; Fulcher G; Shaw W; Oh R; Desai M; Matthews DR; Neal B
Stroke; 2019 Feb; 50(2):396-404. PubMed ID: 30591006
[TBL] [Abstract][Full Text] [Related]
30. Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis.
de Jong MA; Petrykiv SI; Laverman GD; van Herwaarden AE; de Zeeuw D; Bakker SJL; Heerspink HJL; de Borst MH
Clin J Am Soc Nephrol; 2019 Jan; 14(1):66-73. PubMed ID: 30559106
[TBL] [Abstract][Full Text] [Related]
31. Study Protocol for the Effects of Formula Diet with Dapagliflozin on Metabolic Improvement and Body Composition in Type 2 Diabetes Mellitus.
Watanabe Y; Kuribayashi N; Uchida D; Suzuki D; Kato M; Nagayama D; Ohashi H; Ohira M; Saiki A; Tatsuno I
Diabetes Ther; 2019 Feb; 10(1):311-321. PubMed ID: 30574667
[TBL] [Abstract][Full Text] [Related]
32. Analysis of patients with drug-induced pemphigoid using the Japanese Adverse Drug Event Report database.
Tanaka H; Ishii T
J Dermatol; 2019 Mar; 46(3):240-244. PubMed ID: 30575097
[TBL] [Abstract][Full Text] [Related]
33. The Possible Effects of Dapagliflozin on 12-derived Electrocardiogram in Patients with Type 2 Diabetes Mellitus.
Akkuş O; Akkuş G; Kaypaklı O
Endocr Metab Immune Disord Drug Targets; 2019; 19(2):207-213. PubMed ID: 30569879
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom.
Pawaskar M; Bilir SP; Kowal S; Gonzalez C; Rajpathak S; Davies G
Diabetes Obes Metab; 2019 Apr; 21(4):1010-1017. PubMed ID: 30565386
[TBL] [Abstract][Full Text] [Related]
35. Case of acute unilateral emphysematous pyelonephritis and bacteraemia on treatment with canagliflozin.
Gupta R; Ghosh A; Misra A
Postgrad Med J; 2018 Dec; 94(1118):714-715. PubMed ID: 30573559
[No Abstract] [Full Text] [Related]
36. Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study.
Fralick M; Kim SC; Schneeweiss S; Kim D; Redelmeier DA; Patorno E
Ann Intern Med; 2019 Feb; 170(3):155-163. PubMed ID: 30597484
[TBL] [Abstract][Full Text] [Related]
37. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
Pancholia AK
Indian Heart J; 2018; 70(6):915-921. PubMed ID: 30580866
[TBL] [Abstract][Full Text] [Related]
38. Heart failure and type 2 diabetes: From cardiovascular outcome trials, with hope.
Giugliano D; Meier JJ; Esposito K
Diabetes Obes Metab; 2019 May; 21(5):1081-1087. PubMed ID: 30609236
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular outcome trials of glucose-lowering medications: an update.
Home P
Diabetologia; 2019 Mar; 62(3):357-369. PubMed ID: 30607467
[TBL] [Abstract][Full Text] [Related]
40. Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease.
Patoulias D; Kalogirou M
Prz Gastroenterol; 2018; 13(4):337-339. PubMed ID: 30581509
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
